BridgeBio
BBIO
$69.71
-6.45%
BridgeBio Pharma is a biotechnology company focused on discovering, developing, and delivering transformative treatments for patients with genetic diseases, operating within the high-risk, high-reward biotechnology industry. The company has established itself as a platform-based biotech with a portfolio targeting Mendelian disorders, oncology, and gene therapy, distinct for its ability to rapidly advance multiple late-stage programs. The current investor narrative is overwhelmingly centered on the successful Phase 3 trial data for its achondroplasia (dwarfism) treatment and the planned FDA filing in 2026, which has propelled the stock near its 52-week high and solidified its position as a key player in the rare disease market, with significant attention also on the commercial trajectory of its lead asset, acoramidis, for transthyretin amyloid cardiomyopathy.…
BBIO
BridgeBio
$69.71
Related headlines
Investment Opinion: Should I buy BBIO Today?
Rating: Hold. The core thesis is that BridgeBio possesses a transformative pipeline with blockbuster potential, but its extreme valuation and deep losses create an asymmetric risk/reward profile that favors waiting for a better entry point or clearer path to profitability.
Supporting Evidence: 1) Valuation is extreme at a PS ratio of 30.05x, far above typical biotech ranges. 2) Revenue growth is accelerating at 25.21% YoY, demonstrating commercial execution. 3) Profitability remains elusive with a -145.26% net margin. 4) Analyst sentiment is unanimously bullish among 15 covering firms, but their high EPS estimate of $10.96 implies significant future success already priced in. The stock trades near its 52-week high, offering limited near-term upside without new catalysts.
Risks & Conditions: The two biggest risks are valuation multiple compression and a delay in the path to profitability. This Hold rating would upgrade to Buy if the PS ratio compresses meaningfully below 20x on non-fundamental weakness, or if the company announces profitability guidance sooner than expected. It would downgrade to Sell if quarterly revenue growth decelerates below 15% or if cash burn accelerates unexpectedly. Relative to its history and biotech peers, BBIO is significantly overvalued, pricing in perfection.
Sign up to view all
BBIO 12-Month Price Forecast
The outlook is balanced with a tilt toward the base case. The company's fundamentals are improving dramatically, but the valuation has run far ahead, embedding success. The 60% base case probability reflects the expectation of continued execution but limited multiple expansion. The stance would upgrade to bullish on a meaningful pullback that improves the risk/reward profile or on confirmation of faster-than-expected profitability. It would turn bearish if the upcoming commercial metrics fail to support the growth narrative, likely triggering the bear case scenario.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on BridgeBio's 12-month outlook, with a consensus price target around $90.62 and implied upside of +30.0% versus the current price.
Average Target
$90.62
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$56 - $91
Analyst target range
The stock is covered by 15 analysts, and the institutional sentiment is overwhelmingly bullish, as evidenced by a series of recent 'Outperform', 'Overweight', and 'Buy' ratings from firms including Mizuho, JP Morgan, and Morgan Stanley, with no downgrades or sell ratings visible in the recent data. While a specific consensus target price is not provided in the dataset, the high level of coverage and uniformly positive recent actions signal strong institutional conviction in the company's near-term prospects, particularly following the positive Phase 3 data readout. The wide dispersion in estimated EPS for the coming period, with a low of $6.08 and a high of $10.96, highlights the significant uncertainty and modeling variability inherent in forecasting a pre-profitability biotech's financials, where the high target likely assumes robust commercial uptake and pipeline success, while the low target may factor in competitive or execution risks.
Bulls vs Bears: BBIO Investment Factors
The evidence currently leans bullish, driven by transformative clinical success, accelerating commercial revenue, and overwhelmingly positive analyst sentiment. However, the bear case is formidable, anchored by an extreme valuation that demands flawless execution. The single most important tension in the investment debate is whether BBIO's blockbuster pipeline potential and accelerating 25%+ revenue growth can justify its ~30x sales multiple before cash burn or a clinical setback triggers a severe derating. The stock's fate hinges on the market's patience for profitability versus its appetite for high-growth, high-risk biotech narratives.
Bullish
- Explosive Revenue Growth & Commercial Launch: Q4 2025 revenue surged 25.21% YoY to $154.18M, a stark contrast to minimal revenue in 2024, driven by the successful launch and scaling of its product segment. This demonstrates the company's transition from a pure R&D entity to a commercial-stage biotech with a validated market for its therapies.
- Overwhelmingly Bullish Analyst Sentiment: All 15 covering analysts have issued recent 'Outperform', 'Overweight', or 'Buy' ratings, with no downgrades or sell ratings. This strong institutional conviction is anchored by positive Phase 3 data for its achondroplasia treatment and the planned FDA filing in 2026, signaling high confidence in near-term catalysts.
- Powerful Long-Term Technical Uptrend: The stock has gained 103.78% over the past year, massively outperforming the S&P 500's 30.59% return. Trading at 86% of its 52-week high ($84.94) indicates sustained momentum and investor optimism, positioning it for a potential breakout if key resistance is breached.
- Exceptional Gross Margin Profile: The company boasts a gross margin of 94.37%, typical for a successful commercial-stage biotech with transformative therapies. This high-margin structure provides a clear path to future profitability once R&D costs are covered and revenue scales further.
Bearish
- Extreme Valuation Premium: With a trailing PS ratio of 30.05x and EV/Sales of 30.23x, BBIO trades at a massive premium to typical biotech industry multiples. This valuation embeds near-perfect execution and leaves the stock vulnerable to severe multiple compression if growth expectations falter.
- Deep, Sustained Unprofitability: The company reported a Q4 2025 net loss of $197.24M and a trailing net margin of -145.26%. Despite high revenue growth, the path to profitability remains distant, with a trailing twelve-month free cash flow burn of -$457.60M, indicating continued heavy reliance on external financing.
- High Volatility & Recent Consolidation: The stock exhibits a 20.25% maximum drawdown from recent highs and a negative 3-month return of -5.89%, diverging from its strong annual trend. This signals profit-taking and heightened sensitivity to sentiment shifts, typical of high-beta (1.094) biotech stocks facing execution risks.
- Significant Cash Burn & Negative Equity: The negative debt-to-equity ratio of -1.31 and substantial negative free cash flow highlight a capital-intensive business model. The company must continue to raise capital, risking shareholder dilution, to fund its ambitious pipeline before its commercial assets generate sufficient cash.
BBIO Technical Analysis
The stock is in a sustained, powerful long-term uptrend, evidenced by a staggering 103.78% gain over the past year, significantly outperforming the broader market's 30.59% return. With a current price of $73.28, the stock is trading at approximately 86% of its 52-week high of $84.94, indicating strong momentum and positioning near recent highs, which suggests investor optimism but also raises the risk of a near-term pullback from overbought conditions. The 1-month price change of +2.33% and 3-month change of -5.89% reveal a significant short-term divergence from the explosive annual trend, signaling a period of consolidation and potential profit-taking after the recent surge, especially given the stock's relative strength versus the S&P 500 was negative (-6.37) over the past month. Key technical levels are clearly defined by the 52-week high of $84.94 as immediate resistance and the 52-week low of $31.77 as major support; a decisive breakout above resistance would confirm the resumption of the primary uptrend, while a breakdown below the recent consolidation range could signal a deeper correction. The stock's beta of 1.094 indicates volatility roughly in line with the broader market, but the dramatic 20.25% maximum drawdown from recent highs highlights its inherent sensitivity to clinical and market sentiment shifts, which is critical for risk management.
Beta
1.09
1.09x market volatility
Max Drawdown
-20.3%
Largest decline past year
52-Week Range
$32-$85
Price range past year
Annual Return
+94.2%
Cumulative gain past year
| Period | BBIO Return | S&P 500 |
|---|---|---|
| 1m | +0.0% | +12.2% |
| 3m | -10.0% | +2.3% |
| 6m | +10.0% | +4.7% |
| 1y | +94.2% | +29.2% |
| ytd | -10.9% | +4.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BBIO Fundamental Analysis
Revenue growth has accelerated dramatically, with Q4 2025 revenue reaching $154.18 million, representing a 25.21% year-over-year increase, a stark contrast to the minimal revenue figures from the same period in 2024, driven primarily by the launch and scaling of its product segment, which contributed $254.26 million over a recent period. The company remains deeply unprofitable, reporting a Q4 2025 net loss of $197.24 million and a trailing net margin of -145.26%, although its gross margin of 94.37% is exceptionally high and typical for a commercial-stage biotech, reflecting the favorable economics of its therapies once they overcome the massive upfront R&D costs. The balance sheet shows a strong current ratio of 2.62, indicating good short-term liquidity, but the company is burning significant cash with a trailing twelve-month free cash flow of -$457.60 million and a negative debt-to-equity ratio of -1.31, underscoring its continued reliance on external financing to fund its ambitious clinical pipeline and commercial operations despite its improving revenue base.
Quarterly Revenue
$154180000.0B
2025-12
Revenue YoY Growth
+25.21%
YoY Comparison
Gross Margin
+0.90%
Latest Quarter
Free Cash Flow
$-457602000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BBIO Overvalued?
Given the company's negative net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is an elevated 30.05x, while the forward-looking metric, Enterprise Value-to-Sales (EV/Sales), is similarly high at 30.23x, indicating the market is pricing in substantial future revenue growth with little expectation of near-term multiple compression. Compared to typical biotechnology industry averages, which often range in the mid-to-high single digits for PS ratios, BridgeBio's ~30x multiple represents a significant premium, justified only by its blockbuster potential in rare diseases, accelerating revenue trajectory, and a late-stage pipeline with multiple near-term catalysts. Historically, the stock's own PS ratio has compressed dramatically from extreme levels above 1,800x in 2024 when revenue was minimal, to the current ~30x, suggesting the valuation has normalized somewhat with commercial execution, yet it remains near the higher end of its recent historical range, reflecting high expectations that must be met with continued execution.
PE
-20.7x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -38x~-2x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-25.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe. BridgeBio remains deeply unprofitable with a net margin of -145.26% and burned -$457.60M in free cash flow over the trailing twelve months. Despite a strong current ratio of 2.62, the negative debt-to-equity ratio of -1.31 underscores a balance sheet reliant on future equity or debt raises, risking shareholder dilution. Revenue, while growing at 25.21% YoY, must continue accelerating exponentially to justify the current valuation before the cash runway depletes.
Market & Competitive Risks center on valuation compression. Trading at a PS ratio of 30.05x, a significant premium to industry averages, the stock is highly sensitive to shifts in growth stock sentiment and interest rates. Its beta of 1.094 indicates market-correlated volatility, and recent news highlights its susceptibility to being among 'large-cap losers' during market downturns. Competitive risks are inherent, as the success of its lead achondroplasia program depends on securing FDA approval by 2026 and capturing market share in a specialized but potentially crowded rare disease space.
Worst-Case Scenario involves a combination of a clinical setback for its key pipeline asset (e.g., FDA rejection or disappointing commercial uptake for acoramidis), leading to analyst downgrades, a collapse in its premium valuation multiple, and a liquidity crunch as cash burn continues. This could trigger a rapid decline toward its 52-week low of $31.77. From the current price of $73.28, this represents a realistic downside of approximately -57%. Even a less severe correction to recent support levels could mean a loss of 20-30%, as evidenced by the stock's 20.25% maximum drawdown.
FAQ
The key risks are: 1) Valuation Risk: The extreme ~30x sales multiple is vulnerable to compression if growth slows, posing a -50%+ downside risk. 2) Financial Risk: Sustained deep losses (-145% net margin) and high cash burn (-$457M TTM FCF) necessitate future fundraising, risking dilution. 3) Clinical/Regulatory Risk: The entire thesis depends on successful FDA approval and commercial uptake of its lead therapies; any setback would be catastrophic. 4) Market Risk: As a high-beta (1.094) growth stock, it is sensitive to sector rotations and rising interest rates.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $70 and $85, as the company executes its plans but valuation caps gains. The Bull Case (25% probability) could drive the stock to $95-$110 on superior commercial execution and positive pipeline news. The Bear Case (15% probability) risks a decline to $40-$55 on a growth scare or funding crisis. The base case is most likely, implying modest upside from current levels but high volatility. The wide analyst EPS estimate range ($6.08 to $10.96) underscores the forecasting uncertainty.
BBIO is significantly overvalued based on standard financial metrics. Its trailing Price-to-Sales ratio of 30.05x and EV/Sales of 30.23x represent a massive premium to the biotechnology industry. This valuation implies the market expects flawless execution, blockbuster sales from its pipeline, and a rapid path to profitability. Compared to its own history, the multiple has compressed from extreme levels but remains elevated. The stock is priced for perfection, leaving little room for error.
BBIO is a speculative buy only for investors with a high risk tolerance and a long-term horizon. The stock has massive upside potential if its pipeline succeeds, as reflected in unanimous analyst bullishness. However, at a current PS ratio of 30x, it is severely overvalued by traditional metrics and carries a high risk of a sharp correction if execution stumbles. The most attractive entry point would be on a significant pullback that reduces valuation risk. The current price near the 52-week high offers a poor risk/reward for new money.
BBIO is strictly a long-term investment, with a suggested minimum holding period of 3-5 years to allow its clinical and commercial milestones to unfold. The stock's high beta (1.094) and 20.25% drawdown potential make it unsuitable for short-term trading or risk-averse portfolios. It pays no dividend and its value is entirely tied to future pipeline success. Only investors who can withstand significant volatility and are betting on multi-year FDA approvals and market penetration should consider holding BBIO.